Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Rhea-AI Summary

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has announced its participation in two upcoming investor conferences in April 2025.

CEO and Co-founder Brian Sullivan will present at:

• The Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:00 a.m. ET
• The 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025, at 11:00 a.m. ET

Both presentations will be available via live webcast and can be accessed through the company's investor relations website, with replays available after the events.

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel99/celc/2065375; and
• A fireside chat at the 24^th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/needham146/celc/2212811.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity 

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.

View source version of release on GlobeNewswire.com

Contacts: 
Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284

FAQ

When is Celcuity (CELC) presenting at the Stifel Virtual Targeted Oncology Forum 2025?

Celcuity will present at the Stifel Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:00 a.m. ET.

How can investors watch Celcuity's (CELC) presentation at the Needham Healthcare Conference?

Investors can watch the presentation live through the webcast link or access it from Celcuity's investor relations website at ir.celcuity.com/events-presentations/.

Will Celcuity (CELC) offer one-on-one meetings with investors at these conferences?

Yes, Celcuity will be available for one-on-one investor meetings at both conferences.

Where can investors find the replay of Celcuity's (CELC) conference presentations?

Replays will be available shortly after the live events in the Investors section of Celcuity's website at ir.celcuity.com/events-presentations/.